Kineta to Participate in BIO Investor Forum Digital

Seattle, WA — (October 2, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be participating in the BIO Investor Forum Digital on October 13-15, 2020. Shawn Iadonato, Kineta Chief Executive Officer and Jacques Bouchy, SVP Business Development and Corporate Communications will be meeting with investors and other stakeholders to present an overview of the company with a focus on its novel VISTA immuno-oncology program.

About BIO Investor Forum Digital
BIO Investor Forum Digital, October 13-15, provides three days of enhanced BIO One-on-One Partnering, interactive educational sessions and Fireside Chats and 160 on-demand company presentations showcasing their drug development programs ready for partnering or venture funding. There is no better virtual event for biotech innovators looking for investors and strategic partners to advance their company to the next stage in their business life cycle. Visit bio.org/investor forum to learn more.

####

Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta does not undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400